SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc lessened its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 88.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,041 shares of the company's stock after selling 145,903 shares during the quarter. Ensign Peak Advisors Inc's holdings in SpringWorks Therapeutics were worth $688,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Huntington National Bank grew its stake in SpringWorks Therapeutics by 38.2% during the 4th quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after buying an additional 192 shares during the last quarter. AlphaQuest LLC lifted its stake in SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after acquiring an additional 414 shares during the period. Barclays PLC boosted its holdings in shares of SpringWorks Therapeutics by 0.3% in the 4th quarter. Barclays PLC now owns 156,123 shares of the company's stock valued at $5,641,000 after acquiring an additional 447 shares during the last quarter. Virtus ETF Advisers LLC raised its holdings in shares of SpringWorks Therapeutics by 7.4% during the fourth quarter. Virtus ETF Advisers LLC now owns 9,037 shares of the company's stock worth $327,000 after purchasing an additional 622 shares during the last quarter. Finally, KBC Group NV lifted its position in SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after purchasing an additional 978 shares during the period.

SpringWorks Therapeutics Stock Performance

Shares of SWTX traded up $0.08 during mid-day trading on Thursday, hitting $46.29. 1,540,169 shares of the company were exchanged, compared to its average volume of 2,136,006. The stock has a market cap of $3.49 billion, a price-to-earnings ratio of -13.30 and a beta of 0.77. SpringWorks Therapeutics, Inc. has a 1-year low of $28.21 and a 1-year high of $62.00. The company has a 50 day moving average of $43.69 and a 200-day moving average of $42.49.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The firm had revenue of $49.09 million for the quarter, compared to analyst estimates of $64.19 million. Research analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

SWTX has been the topic of several analyst reports. Cowen downgraded SpringWorks Therapeutics to a "hold" rating in a research report on Tuesday, April 29th. TD Cowen reaffirmed a "hold" rating and set a $47.00 target price (down from $66.00) on shares of SpringWorks Therapeutics in a report on Tuesday, April 29th. Wedbush reiterated a "neutral" rating and set a $47.00 price target (down from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Barclays restated an "equal weight" rating and issued a $47.00 price objective (down previously from $63.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Finally, HC Wainwright reaffirmed a "neutral" rating and set a $47.00 price objective (down previously from $74.00) on shares of SpringWorks Therapeutics in a research note on Wednesday, April 30th. Seven investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $52.57.

Insider Activity

In other news, COO Badreddin Edris sold 20,000 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $54.23, for a total value of $1,084,600.00. Following the sale, the chief operating officer now directly owns 169,712 shares of the company's stock, valued at approximately $9,203,481.76. The trade was a 10.54% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Saqib Islam sold 49,000 shares of SpringWorks Therapeutics stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $54.24, for a total value of $2,657,760.00. Following the completion of the transaction, the chief executive officer now owns 954,869 shares of the company's stock, valued at approximately $51,792,094.56. This trade represents a 4.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 7.83% of the company's stock.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.